NLS PHARMACEUTICS LTD (NLSP) Stock Income Statement
NASDAQ:NLSP - Nasdaq - CH1384053976 - Common Stock - Currency: USD
| TTM (2024-6-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 6.31M | 11.81M | 15.48M | 11.86M | 2.30M | |||
| Research and Development | 1.80M | 5.91M | 8.98M | 5.92M | 100.00K | |||
| Selling, General, and Administrative Expenses | 4.51M | 5.90M | 6.51M | 5.94M | 2.20M | |||
| Operating Income | -6.31M | -11.81M | -15.48M | -11.86M | -2.30M | |||
| Interest Income/Expense | -232.00K | -145.20K | -90.00K | -90.00K | -560.00K | |||
| Other Income/Expense | -52.10K | -219.80K | N/A | N/A | N/A | |||
| Non Recurring Items | N/A | 0.00 | -920.00K | 0.00 | 0.00 | |||
| Income Before Taxes | -6.60M | -12.17M | -16.50M | -11.95M | -2.86M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -6.60M | -12.17M | -16.50M | -11.95M | -2.86M | |||
| EBITDA | -6.30M | -11.80M | -15.47M | -11.85M | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -6.72 | -12.75 | -0.84 | -1.00 | -0.24 | |||
| Statistics | ||||||||
All data in USD